The results of this study indicate that the upregulation of β3-AR after BRL37344 application plays a protective role, ameliorating pathological damage such as liver steatosis, in the rat model of HFD-induced NAFLD, similar to the results of Cuiying Xiao et al. A recent study (Decara et al. 2018) revealed that treatment with a combination of the β3-AR agonist CL316243 and liraglutide (a human glucagon-like peptide-1 [GLP-1] analog) for one week decreased liver lipid content and serum transaminase and lipid levels in rats, similar to the results of our study. Here, GCG is linked to metabolic dysfunction-associated steatotic liver disease.